Stocks and Investing
Stocks and Investing
Mon, June 14, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Sun, June 13, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, June 11, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Paul Matteis Maintained (VRTX) at Strong Buy with Decreased Target to $244 on, Jun 11th, 2021
Paul Matteis of Stifel, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Decreased Target from $277 to $244 on, Jun 11th, 2021.
Paul has made no other calls on VRTX in the last 4 months.
There are 2 other peers that have a rating on VRTX. Out of the 2 peers that are also analyzing VRTX, 0 agree with Paul's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Paul
- Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $279 on, Wednesday, May 12th, 2021
- Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $260 on, Monday, May 3rd, 2021
Contributing Sources